Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2017-02-27 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to a board meeting agenda item concerning a strategic cooperation agreement with a related party. It references compliance with company law, securities law, and stock exchange listing rules. The content focuses on governance and board-level approval processes rather than financial results, audit, or shareholder voting outcomes. The document is short (794 characters) and does not contain financial data or detailed report content. It is not an announcement of voting results or a proxy solicitation. The nature of the document aligns with Board/Management Information (MANG), as it relates to board-level decisions and approvals.
2017-02-27 Chinese
独立董事关于第二届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on matters discussed at the company's second board of directors' seventh meeting. It includes opinions on the nomination of a new director and a strategic cooperation agreement with a related party. The content focuses on governance and board-level decisions rather than financial results or regulatory filings. The document is relatively short (1377 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results, nor a proxy solicitation, but rather a board/management related information document. Therefore, the most appropriate classification is Board/Management Information (MANG).
2017-02-27 Chinese
关于埃克替尼纳入国家医保《药品目录》的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the inclusion of a pharmaceutical product (埃克替尼) into the national medical insurance drug catalog. It contains no financial statements, no detailed financial data, no management discussion, or regulatory certifications. It is a regulatory announcement about product listing and its potential impact on business, typical of a general regulatory filing. The document is short (648 characters) and does not present any report or financial results. Therefore, it fits best under Regulatory Filings (RNS).
2017-02-23 Chinese
关于使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle raised funds for cash management, specifically detailing the purchase and redemption of bank wealth management products. It includes investment risk analysis, risk control measures, and the impact on company operations. The document is relatively short (2821 characters) and focuses on disclosing updates about the use of idle raised funds rather than presenting comprehensive financial statements or detailed financial performance. It does not contain full financial reports or earnings data. Therefore, it is best classified as a Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including the use of raised funds for cash management.
2017-02-21 Chinese
关于埃克替尼进入各地医保情况的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Betta Pharmaceuticals Co., Ltd. regarding the inclusion of their product, Erlotinib, into various local medical insurance reimbursement lists across different provinces and cities in China. It provides a detailed table of dates and regions where the product has been included in medical insurance schemes. The document emphasizes the potential impact on sales and advises investors to be cautious. There is no financial data, no mention of annual or quarterly results, no management discussion, no audit information, and no regulatory certifications. The document is an announcement about a product's market and reimbursement status, which is a regulatory announcement related to company operations but not fitting into other specific categories like earnings, management changes, or capital updates. Given the content and length (1391 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous announcements that do not fit other specific types.
2017-02-02 Chinese
关于公司部分高管辞职的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the company regarding the resignation of certain senior management personnel, including their positions and effective dates. It does not contain financial data, audit information, or details of a report. The content focuses on management changes, specifically resignations of high-level executives. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS. Hence, the classification is MANG with high confidence.
2017-02-02 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.